ASP9801

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Cancer

Conditions

Metastatic Cancer, Solid Tumors, Advanced Cancer

Trial Timeline

Sep 3, 2019 → Apr 19, 2024

About ASP9801

ASP9801 is a phase 1 stage product being developed by Astellas Pharma for Metastatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03954067. Target conditions include Metastatic Cancer, Solid Tumors, Advanced Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Cancer were approved

Approved (20) Terminated (8) Active (0)
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
Enfortumab VedotinAstellas PharmaApproved
EligardAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03954067Phase 1Completed

Competing Products

20 competing products in Metastatic Cancer

See all competitors